A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 578 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR How Do Black People with Cancer View Clinical Research? November 15, 2024 Dad Sings “Ave Maria” For His Daughter At Disney World April 8, 2019 Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors March 27, 2025 Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... July 3, 2023 Load more HOT NEWS Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in... Reunión anual de la American Society of Clinical Oncology de 2023:... EMA Recommends Extension of Indications for Idecabtagene Vicleucel Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation...
